Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience

---

Ozcelik S., Celik M., Vural A., Aydin B., Ozcelik M., GÖZÜ H.

ARCHIVES OF MEDICAL SCIENCE, cilt.17, sa.1, ss.1-8, 2021 (SCI-Expanded, Scopus)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 17 Sayı: 1
• Basım Tarihi: 2021
• Doi Numarası: 10.5114/aoms.2020.93264
• Dergi Adı: ARCHIVES OF MEDICAL SCIENCE
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, Veterinary Science Database, Directory of Open Access Journals
• Sayfa Sayıları: ss.1-8
• Anahtar Kelimeler: Intensive, degludec, co-formulation, premixed, DEGLUDEC/INSULIN ASPART, GLUCOSE VARIABILITY, PHASE 3A, HYPOGLYCEMIA, TARGET, BASAL, MANAGEMENT, GLARGINE, PEOPLE, ADULTS
• Marmara Üniversitesi Adresli: Evet

Özet

Introduction: To evaluate the efficacy and safety of transition from premixed and intensive insulin to twice-daily insulin degludec/aspart (IDegAsp) co-formulation in patients with type 2 diabetes mellitus.